首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats.
【24h】

Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats.

机译:氨基胍可改善麻醉性门脉高压大鼠的门脉高压,而不会改善门脉高压和门脉高压性胃病。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: Portal hypertension and hyperdynamic circulation (i.e. generalized vasodilation and increased cardiac output and regional organ blood flows) may play an important role in the development of portal hypertensive gastropathy. This study investigated the effect of chronic administration of aminoguanidine, a selective inducible nitric oxide synthase inhibitor, to portal hypertensive rats on hemodynamics and the development of portal hypertensive gastropathy. METHODS: Partial portal vein-ligated or sham-operated rats were randomly assigned to receive either placebo (distilled water) or aminoguanidine (approximately 100 mg/kg per day subcutaneously) for 2 days prior to and 14 days. Hemodynamic studies with a thermodilution technique and gastric morphometric analysis were performed at 14 days after the operation. RESULTS: In rats given placebo, portal vein-ligated rats had a significantly lower mean arterial pressure and systemic vascular resistance associated with a significantly higher cardiac index and portal pressure than sham-operated rats (p<0.05). In portal vein-ligated rats aminoguanidine induced a significant increase in mean arterial pressure and systemic vascular resistance accompanied by a significant decrease in cardiac index (p<0.05) without changes in portal pressure (p>0.05). Despite persistence of portal hypertension, the aminoguanidine-treated portal vein-ligated rats had similar mean arterial pressure, cardiac index, and systemic vascular resistance as seen in placebo-treated sham-operated rats. The mean cross-sectional area of gastric mucosal vessels was significantly higher in placebo-treated portal vein-ligated than in placebo-treated sham-operated rats (p<0.05). Treatment with aminoguanidine did not induce changes in the mean cross-sectional area of gastric mucosal vessels in either portal vein-ligated or sham-operated rats (p>0.05). CONCLUSIONS: The results show that in portal hypertensive rats long-term aminoguanidine therapy corrects the hyperdynamic circulation without inducing changes in portal pressure and ameliorating the development of portal hypertensive gastropathy. This study suggests that, instead of correcting hyperdynamic circulation, treatment of portal hypertensive gastropathy should be aimed at reducing portal pressure.
机译:背景/目的:门脉高压和高动力循环(即全身性血管舒张,心输出量增加和局部器官血流量增加)可能在门脉高压性胃病的发展中起重要作用。这项研究调查了长期向门脉高压大鼠长期施用选择性诱导型一氧化氮合酶抑制剂氨基胍对血流动力学和门脉高压性胃病发展的影响。方法:将部分经门静脉结扎或假手术的大鼠随机分为两组,分别在安慰剂(蒸馏水)或氨基胍(皮下每天100 mg / kg,每天皮下注射)接受2天和14天。术后14天进行热稀释技术的血流动力学研究和胃形态分析。结果:在接受安慰剂的大鼠中,与假手术的大鼠相比,结扎门静脉的大鼠的平均动脉压和全身血管阻力显着降低,并且心脏指数和门静脉压明显更高(p <0.05)。在门静脉结扎的大鼠中,氨基胍诱导平均动脉压和全身血管阻力显着增加,同时心脏指数显着下降(p <0.05),而门静脉压不变(p> 0.05)。尽管持续存在门静脉高压症,但经氨基胍治疗的门静脉结扎大鼠的平均动脉压,心脏指数和全身血管阻力与安慰剂治疗的假手术大鼠相似。安慰剂治疗的门静脉结扎患者的胃黏膜血管平均横截面积明显高于安慰剂治疗的假手术大鼠(p <0.05)。在门静脉结扎或假手术的大鼠中,氨基胍治疗均未引起胃粘膜血管平均横截面积的变化(p> 0.05)。结论:结果表明,长期门脉高压大鼠氨基胍治疗可纠正高动力循环,而不会引起门脉压力的改变并改善门脉高压性胃病的发展。这项研究表明,代替纠正高动力循环,门脉高压性胃病的治疗应旨在降低门脉压力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号